Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Operating Leases (2021 - 2026)

Indivior Pharmaceuticals has reported Operating Leases over the past 6 years, most recently at $14.0 million for Q1 2026.

  • For Q1 2026, Operating Leases fell 53.33% year-over-year to $14.0 million; the TTM value through Mar 2026 reached $14.0 million, down 53.33%, while the annual FY2025 figure was $22.0 million, 31.25% down from the prior year.
  • Operating Leases for Q1 2026 was $14.0 million at Indivior Pharmaceuticals, down from $22.0 million in the prior quarter.
  • Over five years, Operating Leases peaked at $34.0 million in Q4 2023 and troughed at -$35.0 million in Q3 2024.
  • A 5-year average of $3.9 million and a median of $22.0 million in 2025 define the central range for Operating Leases.
  • Biggest five-year swings in Operating Leases: skyrocketed 193.75% in 2025 and later plummeted 53.33% in 2026.
  • Year by year, Operating Leases stood at $29.0 million in 2022, then grew by 17.24% to $34.0 million in 2023, then fell by 5.88% to $32.0 million in 2024, then crashed by 31.25% to $22.0 million in 2025, then crashed by 36.36% to $14.0 million in 2026.
  • Business Quant data shows Operating Leases for INDV at $14.0 million in Q1 2026, $22.0 million in Q4 2025, and $24.0 million in Q3 2025.